USD10
GLSI acciones
Acerca de Greenwich LifeSciencesGreenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
USD10
GLSI acciones
Acerca de Greenwich LifeSciencesGreenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Estadísticas
VENTANA DE OPERACIÓN
Cerrado
ABRE A LAS
No hay suficientes datos
CAPITALIZACIÓN DE MERCADO
330,43 M US$
PRECIO DE APERTURA
25,68 US$
BAJO (1Y)
7,78 US$
ALTO (1Y)
34,10 US$
BAJO (24H)
23,85 US$
Alza (24H)
26,33 US$
Volumen (24 h)
144,26 mil US$
24,36 %
Historial de precios
Time | Price | Change |
|---|---|---|
Hoy | 25,68 US$ | |
1 día | 24,10 US$ | |
1 semana | 26,76 US$ | |
1 mes | 24,44 US$ | |
1 año | 11,25 US$ |